RedHill's Opaganib Selected for Evaluation by BARDA
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation
Opaganib is the first oral pill-based therapy to significantly reduce mortality outcomes in hospitalised COVID-19 patients.